When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

from Eli Lilly before 27 September. Novartis and Amgen already have a CGRP drug on the market – Aimovig (erenumab) was approved in the US in May. Teva has priced its monthly injection at $575 ...

The drug was first approved in the 1990s and is currently marketed by Eli Lilly under the brand name Zyprexa. Teva, which launched a Dr. Reddy’s-partnered generic to Zyprexa in 2011, spotted a ...

This allowed Regeneron and Teva to continue with trials on fasinumab, and Pfizer and Eli Lilly to resume trials into tanezumab. The latest results from Regeneron and Teva are from a sub-study in a ...

Eli Lilly partners with VC to launch 700 billion won biotech ecosystem fund Eli Lilly collaborates with a16z to create a vast ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second ...

CGRP Inhibitors Market. The global CGRP inhibitors market is poised for robust growth, with its valuation expected to rise ...

Teva Pharmaceuticals’ TEV-479 (olanzapine ... in 2009. It is marketed by Eli Lilly as Zyprexa and a longer-acting version ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...